Focal nodular liver hyperplasia as a late complication that occurs after autologous hematopoietic stem cell transplantation in children with neuroblastoma (clinical case and literature review)-Reference-Cited by-同舟云学术

Focal nodular liver hyperplasia as a late complication that occurs after autologous hematopoietic stem cell transplantation in children with neuroblastoma (clinical case and literature review)

Published:2019-09-25 Issue:3 Volume:6 Page:94-102
ISSN:2413-5496
Container-title:Russian Journal of Pediatric Hematology and Oncology
language:
Short-container-title:Ross. ž. det. gematol. onkol.

Author:

Sagoyan G. B.¹,Shamanskaya T. V.²^ORCID,Kachanov D. Yu.²^ORCID,Galyan T. N.³^ORCID,Filin A. V.³^ORCID,Rakov M. A.⁴^ORCID,Feoktistova E. V.²^ORCID,Likar Yu. N.²^ORCID,Varfolomeeva S. R.¹^ORCID

Affiliation:

1. Research Institute of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

2. Russian Scientific Center of Surgery named after Academician B.V. Petrovsky, Ministry of Health of Russia

3. Bryansk Regional Children’s Hospital

4. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

Abstract

Focal nodular hyperplasia (FNH) is a regenerative volumetric liver formation that can occur as a result of the reaction of hepatocytes to local vascular circulatory disorders and is one of the late complications in patients who received high-dose chemotherapy followed by hematopoietic stem cell transplantation. This article presents a description of two clinical cases of development of liver FNH in patients with high-risk neuroblastoma identified in the late stages from the end of specific treatment. A possible reason for the development of liver FNH in these patients could be the use of alkylating drugs (ifosfamide, threosulfan, busulfan, melphalan).

Publisher

OOO Grafika

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference30 articles.

1. Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010;362(23):2202–11. doi: 10.1056/NEJMra0804577.

2. Goodman M.S., Gurney J.G., Smith M.A., Olshan A.F. Sympathetic nervous system tumors. In: Ries L.A.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L. Jr, Bunin G.R., eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program. Bethesda, MD, 1999. Pp. 65–72.

3. Spix C., Pastore G., Sankila R., Stiller C.A., Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081–91. doi: 10.1016/j.ejca.2006.05.008.

4. Matthay K.K., Maris J.M., Schleiermacher G., Nakagawara A., Mackall C.L., Diller L., Weiss W.A. Neuroblastoma. Nat Rev Dis Primers 2016;2:16078. doi: 10.1038/nrdp.2016.78.

5. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165–73. doi: 10.1056/NEJM199910143411601.